Latest News
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
21 August 2026 - Global oncology company Nuvation Bio Inc (NYSE:NUVB) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant s...
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance
21 August 2026 - Maverix Medical, a healthcare company focused on improving the diagnosis and treatment of lung cancer, announced on Thursday that the US Food and Drug Administration (FDA) granted 510(k) clearance on June 30, 2026 for the Maverix Nar...
Upsher-Smith launches Glatiramer Acetate Injection generic
21 August 2026 - Upsher-Smith Laboratories LLC, a US subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472) (OTCQX:BORAY), announced on Thursday the launch of Glatiramer Acetate Injection in 20 mg/mL and 40 mg/mL strengths, adding to the company's ...
Implantica's RefluxStop receives US FDA approval
21 August 2026 - Medical technology company Implantica AG (Nasdaq First North Premier Growth Market: IMP A SDB) announced on Thursday that the US Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop, the company'...
Lupin's VISUfarma signs European licensing deal for presbyopia therapy YUVEZZI
20 August 2026 - Indian pharmaceutical companies Lupin Limited (BSE: 500257; NSE: LUPIN) said on Thursday it has agreed an exclusive licensing deal with commercial-stage ophthalmic pharmaceutical company Tenpoint Therapeutics Ltd., granting Lupin...